Anaptysbio (ANAB) Other financing activities (2016 - 2025)
Anaptysbio posted quarterly Other financing activities of -$1.5 million for Q2 2025, down 4130.56% year-on-year from $36000.0 in Q2 2024, and down 200.0% on a QoQ basis from $1.5 million in Q1 2025.
Anaptysbio (ANAB) has 7 years of Other financing activities data on file, last reported at -$1.5 million in Q2 2025.
- For the quarter ending Q2 2025, Other financing activities fell 4130.56% year-over-year to -$1.5 million; the trailing twelve-month figure through Sep 2025 stood at $7.4 million (up 7085.44% YoY), and the FY2024 full-year result was $7.5 million, changed N/A from the prior year.
- Other financing activities for Q2 2025 stood at -$1.5 million, down from $1.5 million in the prior quarter.
- Across five years, Other financing activities topped out at $7.4 million in Q4 2024 and bottomed at -$1.5 million in Q2 2025.
- The 4-year median for Other financing activities is $39500.0 (2023), against an average of $750400.0.
- The widest annual swing landed in 2023, when Other financing activities soared 2050.0%; it then sank 4130.56% in 2025.
- A 4-year view of Other financing activities shows it stood at -$290000.0 in 2022, then jumped by 85.17% to -$43000.0 in 2023, then soared by 17311.63% to $7.4 million in 2024, then tumbled by 119.61% to -$1.5 million in 2025.
- The last three Other financing activities figures came in at -$1.5 million (Q2 2025), $1.5 million (Q1 2025), and $7.4 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -1.45 Mn |
| Jun 30, 2025 | -1.45 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Sep 30, 2024 | 67,000.00 |
| Sep 30, 2024 | 67,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 36,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Dec 31, 2022 | -290,000.00 |
| Dec 31, 2022 | -290,000.00 |
| Sep 30, 2022 | 288,000.00 |
| Sep 30, 2022 | 288,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2018 | 280,000.00 |
| Mar 31, 2018 | 280,000.00 |
| Dec 31, 2017 | 102,000.00 |
| Dec 31, 2017 | 102,000.00 |
| Sep 30, 2017 | 12,000.00 |
| Sep 30, 2017 | 12,000.00 |
| Jun 30, 2017 | 1.09 Mn |
| Jun 30, 2017 | 1.09 Mn |
| Mar 31, 2017 | 399,000.00 |
| Mar 31, 2017 | 399,000.00 |
| Dec 31, 2016 | -801,000.00 |
| Dec 31, 2016 | -801,000.00 |
| Sep 30, 2016 | 386,000.00 |
| Sep 30, 2016 | 386,000.00 |
| Jun 30, 2016 | 387,000.00 |
| Jun 30, 2016 | 387,000.00 |
| Mar 31, 2016 | 283,000.00 |
| Mar 31, 2016 | 283,000.00 |